Overview
PEHO syndrome (Progressive Encephalopathy with edema, Hypsarrhythmia, and Optic atrophy) is a rare, severe neurodegenerative disorder first described in Finnish families. The acronym captures its cardinal features: progressive encephalopathy (brain dysfunction), subcutaneous edema (particularly of the limbs and face), hypsarrhythmia (a severely abnormal electroencephalographic pattern associated with infantile spasms), and optic atrophy (degeneration of the optic nerves leading to visual impairment or blindness). The condition is caused by biallelic pathogenic variants in the ZNHIT3 gene on chromosome 17q25.1, which encodes a protein involved in small nucleolar ribonucleoprotein (snoRNP) assembly and is essential for normal brain development. Affected infants typically appear normal at birth but develop hypotonia (reduced muscle tone), feeding difficulties, and seizures — often infantile spasms with hypsarrhythmia — within the first weeks to months of life. Progressive cerebellar and cerebral atrophy is evident on brain MRI, and psychomotor development is severely impaired, with most children never achieving independent sitting or purposeful hand use. Dysmorphic features may include a narrow forehead, epicanthal folds, short nose, and open mouth. Peripheral edema of the dorsum of the hands and feet, as well as facial puffiness, is a characteristic finding. Optic atrophy develops during infancy, contributing to severe visual impairment. There is currently no curative treatment for PEHO syndrome. Management is supportive and symptomatic, focusing on seizure control with antiepileptic medications (though seizures are often refractory), nutritional support (frequently requiring gastrostomy tube feeding), physical therapy, and management of respiratory complications. Life expectancy is significantly reduced, though some individuals survive into their teens or beyond with intensive supportive care. The condition is most prevalent in Finland but has been reported worldwide.
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for PEHO syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for PEHO syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for PEHO syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to PEHO syndrome.
Community
No community posts yet. Be the first to share your experience with PEHO syndrome.
Start the conversation →Latest news about PEHO syndrome
No recent news articles for PEHO syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about PEHO syndrome
What is PEHO syndrome?
PEHO syndrome (Progressive Encephalopathy with edema, Hypsarrhythmia, and Optic atrophy) is a rare, severe neurodegenerative disorder first described in Finnish families. The acronym captures its cardinal features: progressive encephalopathy (brain dysfunction), subcutaneous edema (particularly of the limbs and face), hypsarrhythmia (a severely abnormal electroencephalographic pattern associated with infantile spasms), and optic atrophy (degeneration of the optic nerves leading to visual impairment or blindness). The condition is caused by biallelic pathogenic variants in the ZNHIT3 gene on ch
How is PEHO syndrome inherited?
PEHO syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does PEHO syndrome typically begin?
Typical onset of PEHO syndrome is infantile. Age of onset can vary across affected individuals.